News
News / Press Releases
Press Releases
Penumbra Inc. Launches New 5MAX™ Reperfusion Catheter

Penumbra Inc. launches new 5MAX™ Reperfusion Catheter for clot removal in patients with acute ischemic stroke


Alameda, CA – (BUSINESS WIRE) – August 22, 2012

The Penumbra System’s line of new MAX Reperfusion Catheters now includes 5MAX™ for the removal of clots in patients experiencing acute ischemic stroke. The MAX System provides a fast, simplified procedure that applies direct aspiration on the occlusion to optimize thrombus removal without the need for dual operators or the use of a large proximal balloon guide.

The 5MAX Reperfusion Catheter offers the highest aspiration power for neuro-thrombectomy—equivalent to a 0.062” lumen of the same length. The 5MAX accomplishes this with its tapered design allowing for a lower profile, flexible distal section to optimize navigation, and a larger proximal section for aspiration power. The 5MAX’s tapered lumen also allows easy delivery of adjunctive therapies, eliminating the need for re-access. Like all of the MAX line of Reperfusion Catheters, the 5MAX incorporates a new advanced polymer and nitinol coil reinforcement design at the distal tip to enable easy tracking through tortuous vessels.

“The tapered lumen of the 5MAX has great aspiration power for quick and efficient clot removal,” said Quill Turk, DO, Associate Professor of Radiology, Director of Neurointerventional Division, Medical University of South Carolina in Charleston, South Carolina. “The new 5MAX design allows easy intracranial access with a large bore versatile catheter for stroke intervention. When beginning a clot removal procedure, the 5MAX allows me to access the clot and reliably open the vessel. If needed, adjunctive devices can be introduced through the 5MAX easily while retaining the benefit of direct aspiration,” Dr. Turk continued. “I feel that 5MAX provides the widest range of therapeutic options to treat an often challenging disease.”

The Penumbra System technology has shown superior outcomes in the recent START Trial. Interim results reported at the 2012 International Stroke Conference showed 48.1% (37/77) of patients had a modified Rankin Score (mRS) of ≤ 2 at 90 days follow-up, indicating a return to independent life. This is the highest rate of good neurological outcomes in any prospective, multicenter, core-lab adjudicated study of interventional stroke treatment.

The Penumbra System, including the new MAX System, can be used to open the blood vessels of patients with acute ischemic stroke within 8 hours of symptom onset. Advanced stroke centers may use the MAX System in conjunction with intravenous clot-busting drugs, or when those drugs can’t be used.

ABOUT Penumbra, Inc.

Penumbra, Inc. is an independent medical device company committed to delivering clinically beneficial products that help patients suffering from stroke and other vascular diseases. Penumbra’s global headquarters is located in Alameda, California with sales operations in North and South America, Europe, Australia and Asia.


CONTACT:

Penumbra Media Relations:

Rachael Kopeck, 510-748-3200
info@penumbrainc.com

The Ruth Group
Kimberly Muscara, 646-536-7011
kmuscara@theruthgroup.com


SOURCE: Penumbra, Inc.

Copyright Business Wire 2012


Careers | Clinical Data | Professional Meetings | Regional Availability | QuEST2StopStroke.com | Site Map | Contact
©2014 Penumbra Inc. All Rights Reserved | User Agreement | Privacy